Eli Lilly and Company is intensifying its focus on Alzheimer's disease in India, as highlighted by the launch of Lormalzi (donanemab), a new therapy designed to target amyloid plaques in the brain, which are linked to disease progression. Priced at ₹91,688 per 350 mg vial, this treatment is expected to be available through hospitals and pharmacies later this month. Currently, approximately 8.8 million people in India suffer from dementia, with Alzheimer's accounting for 60-70% of these cases. This number is projected to rise to over 19 million by 2036. The company aims to address the significant gap in diagnosis and treatment, as only one in ten dementia patients in India receive timely intervention. Eli Lilly's commitment to Alzheimer's research spans over 30 years, with an investment of nearly $11 billion. The launch of Lormalzi represents a significant step in providing innovative therapies to meet the growing medical needs in India.